Life Sciences and Healthcare

U.S. enhances malaria-fighting toolkit

In an unusual action, the U.S. Food and Drug Administration (FDA) asked an advisory committee to meet twice in two weeks this past summer to discuss nearly identical products with similar indications from two different pharmaceutical companies. During their vote, committee members noted the global need for additional agents for the prevention of malaria.   […]

How regulation, innovation, quality and access are inevitably intertwined

In a global industry like pharmaceuticals, the interdependencies among quality, access, innovation and regulation can have global implications. That message comes through clearly in the 2018 CPhI Annual Report, the compilation of expert forecasts and analyses that the organization puts together. The articles, with their focus on the future direction, technologies, opportunities and threats in […]

The Impact of Disruptive Technology on Healthcare in Developed Versus Developing Nations

What to know: Disruptive technologies continue to be introduced by medtech companies in an effort to address the unique needs of both developed and developing countries. In the developing world, technology is helping rural populations access care and to assist in locating new healthcare facilities. In developed nations, the wealth of patient data is being […]

What we learned about pharma digital at this year’s Digital Pharma East

Last week’s Digital Pharma East conference was a buffet of food for thought about digital health and pharma — we’re still recovering! But we opened our notebooks (and Twitter feeds) to see which themes, trends and insights really popped. Here’s a few: A new model for sharing digital best practices is cropping up at pharmas like […]

Nanotech medical device makers seek guidance in uncertain regulatory environment

There is little in the way of regulatory harmonization regarding nanotechnology regulation at this point, which leaves makers of devices and diagnostics with a complicated path to market. Some jurisdictions are farther along than others, but to date, none of them have covered as much ground as the U.S. Food and Drug Administration (FDA).   […]

Mutual Self-Interest: Joint Venture Payer-Provider Health Plans

As large hospital systems have amassed greater power in their markets through mergers, developing regional integrated delivery networks and starting ACOs, health plans and providers have had to re-think the old oppositional relationship between payers and providers. The last decade’s evolution of performance-based payments and value-based care, together with the technology and systems that make […]

Indivior’s Sublocade contributing to transformation of opioid dependence market

The 2018 Drugs to Watch report, the annual industry forecast and analysis from Clarivate Analytics published in March, forecast 12 new drugs to enter the market in 2018 and achieve blockbuster sales of $1 billion or more by 2022. In a follow-up series we have reviewed the status and landscape of each expected blockbuster with the […]

Is Europe’s PRIME program meeting its objectives?

Since the PRiority MEdicines (PRIME) program scheme was introduced two years ago, more than 40 products have been granted PRIME designation.1  In August 2018, the first two therapies with PRIME designation were granted marketing approval by the European Commission (EC) – Novartis’s Kymriah (tisagenlecleucel) and Kite Pharma/Gilead’s Yescarta (axicabtagene ciloleucel). Yescarta and Kymriah are both […]

11 Unique Tech Solutions That are Transforming India’s Healthcare

Growing opportunities and challenges in the Indian health care system The health care sector in India continues to exhibit impressive growth in both revenue and employment opportunities. With a CAGR of 16% in the period 2008-2022, the Indian health care industry is projected to reach a valuation of $372 billion by 2022 and to create […]

Diseases to Watch: Fatty liver disease and NASH

With Diseases to Watch, we introduce a new series in Life Sciences Connect providing a profile of a disease or therapeutic area which is currently a “hot topic” in the life sciences industry. The first disease profiled was fatty liver disease and NASH where we outline the disease in general and link to a further […]